Translational Stroke Research

, Volume 7, Issue 4, pp 284–293

Extending the Time Window for Endovascular and Pharmacological Reperfusion

SI: Challenges and Controversies in Translational Stroke Research

DOI: 10.1007/s12975-015-0444-4

Cite this article as:
Henninger, N. & Fisher, M. Transl. Stroke Res. (2016) 7: 284. doi:10.1007/s12975-015-0444-4


Pharmacological and device-induced reperfusion therapies have demonstrated increasingly positive outcomes regarding both reperfusion efficacy and 90-day functional outcomes after acute ischemic stroke. However, presently, only a minority of patients are eligible for these treatments. Less than 10 % of all ischemic stroke patients receive intravenous thrombolysis in most centers and it has been projected that only approximately 7–15 % of ischemic stroke patients are eligible for acute endovascular intervention. Making these effective therapies safely available to a much larger number of patients is critical for expanding the benefits of acute ischemic stroke treatment. In this article, we summarize the key results from the clinical trials, challenges, and exciting novel opportunities to increase patient eligibility for these therapies as well as for better outcomes for stroke patients.


Animal modeling Endovascular Ischemic stroke Imaging Neuroprotection Recanalization Reperfusion injury Thrombolysis Tissue-type plasminogen activator Time window 

Copyright information

© Springer Science+Business Media New York 2016

Authors and Affiliations

  1. 1.Department of NeurologyUniversity of Massachusetts Medical SchoolWorcesterUSA
  2. 2.Department of PsychiatryUniversity of Massachusetts Medical SchoolWorcesterUSA
  3. 3.Department of NeurologyBeth Israel Deaconess Medical Center, Harvard Medical SchoolBostonUSA
  4. 4.Division of Stroke and Cerebrovascular Diseases, Department of Neurology, Beth Israel Deaconess Medical CenterHarvard Medical SchoolBostonUSA

Personalised recommendations